vs
Side-by-side financial comparison of John Marshall Bancorp, Inc. (JMSB) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
John Marshall Bancorp, Inc. is the larger business by last-quarter revenue ($16.8M vs $9.1M, roughly 1.8× Protalix BioTherapeutics, Inc.). John Marshall Bancorp, Inc. runs the higher net margin — 36.3% vs -60.3%, a 96.7% gap on every dollar of revenue. Over the past eight quarters, John Marshall Bancorp, Inc.'s revenue compounded faster (15.3% CAGR vs -6.7%).
John Marshall Bancorp, Inc. is a U.S.-based bank holding company that operates through its wholly owned subsidiary John Marshall Bank. It provides a full suite of commercial and consumer banking products including deposit accounts, commercial loans, residential mortgages, and personal financial services, primarily serving retail customers and small-to-mid-sized businesses across the U.S. Mid-Atlantic region.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
JMSB vs PLX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.8M | $9.1M |
| Net Profit | $6.1M | $-5.5M |
| Gross Margin | — | 49.4% |
| Operating Margin | — | -51.1% |
| Net Margin | 36.3% | -60.3% |
| Revenue YoY | — | -49.9% |
| Net Profit YoY | 26.8% | -184.8% |
| EPS (diluted) | $0.43 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $16.8M | — | ||
| Q4 25 | $16.4M | $9.1M | ||
| Q3 25 | $16.3M | $17.9M | ||
| Q2 25 | $15.4M | $15.7M | ||
| Q1 25 | $14.6M | $10.1M | ||
| Q4 24 | $14.3M | $18.2M | ||
| Q3 24 | $13.8M | $18.0M | ||
| Q2 24 | $12.6M | $13.5M |
| Q1 26 | $6.1M | — | ||
| Q4 25 | $5.9M | $-5.5M | ||
| Q3 25 | $5.4M | $2.4M | ||
| Q2 25 | $5.1M | $164.0K | ||
| Q1 25 | $4.8M | $-3.6M | ||
| Q4 24 | $4.8M | $6.5M | ||
| Q3 24 | $4.2M | $3.2M | ||
| Q2 24 | $3.9M | $-2.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% |
| Q1 26 | — | — | ||
| Q4 25 | 47.4% | -51.1% | ||
| Q3 25 | 42.2% | 11.9% | ||
| Q2 25 | 42.7% | 7.5% | ||
| Q1 25 | 42.4% | -41.0% | ||
| Q4 24 | 42.5% | 39.6% | ||
| Q3 24 | 38.8% | 22.2% | ||
| Q2 24 | 39.7% | -18.0% |
| Q1 26 | 36.3% | — | ||
| Q4 25 | 36.2% | -60.3% | ||
| Q3 25 | 33.2% | 13.2% | ||
| Q2 25 | 33.1% | 1.0% | ||
| Q1 25 | 32.9% | -35.8% | ||
| Q4 24 | 33.3% | 35.6% | ||
| Q3 24 | 30.7% | 18.0% | ||
| Q2 24 | 30.9% | -16.4% |
| Q1 26 | $0.43 | — | ||
| Q4 25 | $0.41 | $-0.06 | ||
| Q3 25 | $0.38 | $0.03 | ||
| Q2 25 | $0.36 | $0.00 | ||
| Q1 25 | $0.34 | $-0.05 | ||
| Q4 24 | $0.33 | $0.10 | ||
| Q3 24 | $0.30 | $0.03 | ||
| Q2 24 | $0.27 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $150.2M | $14.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $268.1M | $48.2M |
| Total Assets | $2.4B | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $150.2M | — | ||
| Q4 25 | $130.0M | $14.7M | ||
| Q3 25 | $163.6M | $13.6M | ||
| Q2 25 | $116.9M | $17.9M | ||
| Q1 25 | $169.1M | $19.5M | ||
| Q4 24 | $122.5M | $19.8M | ||
| Q3 24 | $177.2M | $27.4M | ||
| Q2 24 | $182.6M | $23.4M |
| Q1 26 | — | — | ||
| Q4 25 | $80.9M | — | ||
| Q3 25 | $80.9M | — | ||
| Q2 25 | $80.8M | — | ||
| Q1 25 | $80.8M | — | ||
| Q4 24 | $80.8M | — | ||
| Q3 24 | $80.8M | — | ||
| Q2 24 | $24.7M | — |
| Q1 26 | $268.1M | — | ||
| Q4 25 | $265.6M | $48.2M | ||
| Q3 25 | $259.7M | $52.9M | ||
| Q2 25 | $253.7M | $49.9M | ||
| Q1 25 | $253.0M | $45.2M | ||
| Q4 24 | $246.6M | $43.2M | ||
| Q3 24 | $243.1M | $32.4M | ||
| Q2 24 | $235.3M | $28.6M |
| Q1 26 | $2.4B | — | ||
| Q4 25 | $2.3B | $82.3M | ||
| Q3 25 | $2.3B | $82.3M | ||
| Q2 25 | $2.3B | $78.5M | ||
| Q1 25 | $2.3B | $73.9M | ||
| Q4 24 | $2.2B | $73.4M | ||
| Q3 24 | $2.3B | $61.6M | ||
| Q2 24 | $2.3B | $91.5M |
| Q1 26 | — | — | ||
| Q4 25 | 0.30× | — | ||
| Q3 25 | 0.31× | — | ||
| Q2 25 | 0.32× | — | ||
| Q1 25 | 0.32× | — | ||
| Q4 24 | 0.33× | — | ||
| Q3 24 | 0.33× | — | ||
| Q2 24 | 0.11× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $2.0M |
| Free Cash FlowOCF − Capex | — | $1.6M |
| FCF MarginFCF / Revenue | — | 17.8% |
| Capex IntensityCapex / Revenue | — | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $22.6M | $2.0M | ||
| Q3 25 | $1.2M | $-3.7M | ||
| Q2 25 | $7.5M | $-5.2M | ||
| Q1 25 | $7.0M | $-5.1M | ||
| Q4 24 | $17.3M | $4.0M | ||
| Q3 24 | $1.4M | $4.1M | ||
| Q2 24 | $10.2M | $-3.6M |
| Q1 26 | — | — | ||
| Q4 25 | $22.0M | $1.6M | ||
| Q3 25 | $1.2M | $-4.2M | ||
| Q2 25 | $7.4M | $-5.7M | ||
| Q1 25 | $6.6M | $-5.4M | ||
| Q4 24 | $16.8M | $3.6M | ||
| Q3 24 | $1.3M | $4.0M | ||
| Q2 24 | $10.1M | $-3.8M |
| Q1 26 | — | — | ||
| Q4 25 | 134.7% | 17.8% | ||
| Q3 25 | 7.3% | -23.7% | ||
| Q2 25 | 47.8% | -36.2% | ||
| Q1 25 | 45.3% | -53.0% | ||
| Q4 24 | 116.9% | 19.6% | ||
| Q3 24 | 9.5% | 22.4% | ||
| Q2 24 | 80.1% | -28.1% |
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | 4.4% | ||
| Q3 25 | 0.2% | 2.8% | ||
| Q2 25 | 1.0% | 2.8% | ||
| Q1 25 | 2.3% | 3.0% | ||
| Q4 24 | 3.4% | 2.3% | ||
| Q3 24 | 0.8% | 0.5% | ||
| Q2 24 | 0.4% | 1.3% |
| Q1 26 | — | — | ||
| Q4 25 | 3.82× | — | ||
| Q3 25 | 0.23× | -1.58× | ||
| Q2 25 | 1.48× | -31.91× | ||
| Q1 25 | 1.45× | — | ||
| Q4 24 | 3.61× | 0.61× | ||
| Q3 24 | 0.33× | 1.27× | ||
| Q2 24 | 2.60× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JMSB
| Net Interest Income | $16.5M | 98% |
| Noninterest Income | $284.0K | 2% |
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
